Pfizer Derivatives increased by 33.6% to $155.00M in Q1 2026 compared to the prior quarter.
An increase suggests the company is locking in favorable long-term pricing for its operational inputs.
This represents the fair value of derivative financial instruments that are expected to be settled or realized beyond th...
Reflects the duration of the company's hedging strategy compared to industry peers.
other_derivative_assets_noncurrent| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $116.00M | $155.00M |
| QoQ Change | — | +33.6% |